Biocon has received approval from the United States Food and Drug Administration for its generic Everolimus tablets, strengthening the company’s presence in the regulated US pharmaceutical market. The regulatory clearance allows Biocon to commercialize the product for multiple oncology and transplant-related indications, subject to market conditions. The approval highlights Biocon’s growing expertise in complex generics and its ability to meet stringent global regulatory standards.